In a randomized, placebo-controlled, double-masked eight-week study, Blink® NutriTears® —a supplement for dry eyes—was evaluated in adults with clinically diagnosed dry eye disease. Among the 116 adults who completed the study and were included in the analysis, the once-daily supplement significantly improved both of the study's primary outcomes—tear production and overall dry-eye symptoms—compared with placebo at Day 56. Improvements were also seen across several measures of tear-film stability and quality, ocular-surface health and inflammation. The study was published in the peer-reviewed journal Frontiers in Ophthalmology and registered on ClinicalTrials.gov (NCT05481450).*
| Method | |
| Design | Prospective, randomized, placebo-controlled, double-masked, parallel-group clinical study |
| Duration | 56 days (Eight weeks) |
| Participants analyzed | 155 randomized adults ages 18-65 with clinically diagnosed dry eye disease and OSDI score between 12–40. 116 participants completed the study. |
| Study groups | 57 participants took the studied supplement for dry eyes; 59 took placebo |
| Routine | One softgel each morning after food |
| Follow-up visits | Days 14, 28, and 56 |
| Adherence | Average compliance was greater than 96% in both groups |
| Primary outcomes | Tear production using Schirmer’s test and symptoms using the OSDI questionnaire |
| Clinical Measure | Explanation |
|---|---|
| Schirmer's test | Measures tear production by recording how much of a small paper strip is moistened in five minutes. |
| OSDI | A 12-question survey about dry-eye symptoms, vision-related activities and environmental triggers |
| TBUT | Measures how many seconds the tear film stays intact after a blink before the first dry area appears. |
| SPEED | Tracks how often dry-eye symptoms occur and how severe or bothersome they feel. |
| Tear osmolarity | Measures the concentration of particles in tears; higher concentration can be associated with dry eyes. |
| Corneal and conjunctival staining | Uses dye to help an eye care professional assess signs of damage on the eye's surface |
| MMP-9 | A tear-film marker associated with ocular-surface inflammation. |
| Artificial-tear use | Tracks whether and how often participants used rescue artificial tears. |
More tear production. At Day 56, the supplement group showed significantly better improvement in Schirmer's test results—a measure of tear production—than the placebo group (p<0.001 for each eye and the mean of both eyes). The mean of both eyes was also significantly better than placebo at Day 28 (p<0.05).
Improved dry-eye symptoms and daily impact. Overall OSDI scores improved significantly more with the supplement than with placebo beginning at Day 14 (p<0.01), with the difference maintained at Day 28 (p<0.05) and Day 56 (p<0.001). The OSDI symptoms and vision-related function domains also separated from placebo by Day 14; the environmental-triggers domain separated at Day 56.
More stable tears: Tear film break-up time was significantly better with the supplement than placebo for the mean of both eyes and the left eye at Day 28 (p<0.05), and for each eye and the mean of both eyes at Day 56 (p<0.001).
Less frequent and severe symptoms: Total SPEED questionnaire scores improved significantly more than placebo beginning at Day 14 (p<0.05) and remained significantly better at Days 28 and 56. Symptom frequency followed the same timing. Symptom severity separated from placebo at Day 28 and Day 56.
Improved tear quality and ocular-surface signs: At Day 56, tear osmolarity, corneal staining and conjunctival staining were significantly improved compared with placebo (p<0.001 for the mean of both eyes).
A reduction in an inflammation marker: At Day 56, positive MMP-9 test results had decreased from baseline in the supplement group—67.39% in the right eye and 61.36% in the left eye—while they increased in the placebo group. The between-group difference was significant for each eye (p<0.001).
Artificial-tear use did not differ: Participants could use artificial tears as rescue medication during the study. The groups did not differ in frequency of use or in the number of participants using them.
Overall OSDI symptoms and vision-related function scores, plus total SPEED scores and symptom frequency, improved significantly more than placebo. A significant difference in Schirmer's tear production was also reported for the left eye.
Symptom improvements were maintained. Mean Schirmer's tear production for both eyes and selected tear film break-up time measures were significantly better than placebo. SPEED symptom severity also separated from placebo.
Both primary outcomes were significantly improved versus placebo. Significant differences were also reported for tear-film break-up time, osmolarity, corneal and conjunctival staining and MMP-9.
The clinical study evaluated the Blink® NutriTears® formula as a whole.
Each daily softgel provided:
| Ingredient | Studied daily amount |
|---|---|
| Lutein | 20 mg |
| Zeaxanthin isomers |
4 mg |
| Curcuminoids | 200 mg |
| Vitamin D3 | 600 IU |
Separate from the Blink® NutriTears® clinical trial, research on the individual ingredients provides insight into why each matters.*
Research has shown antioxidant and anti-inflammatory effects in ocular cell models, including protection against photo-oxidative damage.1,2
In vitro studies have shown curcumin can reduce the expression of pro-inflammatory cytokines in corneal epithelial cells.3,4
Vitamin D3 supplementation has been shown to improve the efficacy of artificial tears and reduce symptom severity in both vitamin D3-deficient and non-deficient patients.5-7
The supplement was generally well tolerated during the eight-week study. No serious adverse events occurred, and researchers found no clinically meaningful differences between groups in blood safety measures or resting vital signs.
Two of the 116 participants in the analysis reported adverse events. One participant in the supplement group reported three occurrences of mild nasal bleeding and discontinued the study; the paper describes the event as possibly related to the supplement in a participant with a reported history of nasal bleeding triggered by vitamin D3 supplementation. One participant in the placebo group reported one occurrence of mild blurred vision, considered unrelated to the study intervention. Neither participant required drug treatment for the event.
Blink® NutriTears® is intended to be used alongside your current eye care regimen, but it has not been evaluated for children, pregnant individuals, or nursing mothers.
NutriTears® is a once-daily, omega-3-free supplement for dry eyes that is formulated with lutein, zeaxanthin isomers, curcuminoids and vitamin D3 at the amounts studied in the clinical trial. If you already take fish oil, NutriTears® adds its studied blend of nutrients without adding more omega-3 to your daily intake.*
Blink® NutriTears® is a supplement for dry eyes and is intended to be used alongside your current eye care regimen, not as a replacement for prescription or over-the-counter eye drops or other topical treatments recommended by your doctor. If you also take an AREDS/AREDS2 or omega-3 supplement, talk to your doctor: clinical data are not available on taking NutriTears® with AREDS/AREDS2, and use with omega-3 supplements has not been studied, though there is no overlap in ingredients and no known contraindications.*
§Based on a clinical trial; N=116, randomized 1:1 NutriTears® and placebo.
§Based on a clinical study